US-based new independent directorVery interesting that this new independent Board member comes from the US.
TLT once mentioned that NSCLC and GBM ph. 1B trials would be done in the US.
Don't know if we can read anything into this (I doubt). But clearly TLT gave itself a larger and more diversified geographic flavor to suit its ambitions.
TLT has a plan and executes it perfectly now (and since) it has reached its first major milestone; p#25 450-day milestone.
FDA Breakthrough designation will also help us a lot in terms of credibility and visibility.
TLT will need lots of funding to prepare for 2026 but that will be for the ultimate cause; commercialization.
Our phase 2 data is worth hundreds of millions if we jv with a big pharma. Upfront payment will be very welcomed. Until then, we need to secure fundings la carte, depending on the dynamics of events (negotiations, etc ...).